UBS AM
KRSA

UBS AM’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

UBS AM’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-72
Closed -$11.3K – 2708
2022
Q1 		$11.3K Hold
72
– – ﹤0.01% 2776
2021
Q4 		$17.5K Hold
72
– – ﹤0.01% 2836
2021
Q3 		$31.2K Hold
72
– – ﹤0.01% 2737
2021
Q2 		$39.6K Hold
72
– – ﹤0.01% 2743
2021
Q1 		$28.3K Hold
72
– – ﹤0.01% 2597
2020
Q4 		$31.1K Sell
72
-104
-59% -$7.09K ﹤0.01% 2542
2020
Q3 		$150K Hold
176
– – ﹤0.01% 2437
2020
Q2 		$145K Sell
176
-317
-64% -$26.5K ﹤0.01% 2429
2020
Q1 		$183K Buy
493
+188
+62% +$13.4K ﹤0.01% 2297
2019
Q4 		$116K Sell
305
-7,126
-96% -$665K ﹤0.01% 2507
2019
Q3 		$12.6M Buy
7,431
+1,677
+29% +$362K 0.01% 882
2019
Q2 		$9.22M Buy
+5,754
New +$1.63M 0.01% 989

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

UBS AM's KRSA Position: Q2 2022 in Review

UBS AM sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q2 2022, closing a stake of 72 shares — an estimated $11.3K sold.

UBS AM first reported a position in KRSA in Q2 2019 and held it in 12 quarters. The position peaked at $12.6M in Q3 2019. 36 funds tracked by Wall St. Rank hold KRSA as of Q2 2022.

  • UBS AM reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 72 Korsana Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $11.3K.
  • UBS AM first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • UBS AM's Korsana Biosciences, Inc. Common Stock position peaked at $12.6M in Q3 2019.
  • 36 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.